U.S. to implement higher tariffs starting August 1, Commerce Secretary says
The U.S. will begin applying increased tariff rates from August 1, according to Commerce Secretary Howard Lutnick....
Israeli and British scientists have developed a breakthrough blood test capable of detecting Parkinson’s disease in its earliest stages—before symptoms even begin—potentially revolutionizing diagnosis and treatment.
A joint team of researchers from Israel and the UK has unveiled a fast, affordable, and highly accurate blood test that can identify Parkinson’s disease long before clinical symptoms arise, The Press Service of Israel (TPS-IL) reports.
Parkinson’s, a progressive neurodegenerative disorder, affects over 10 million people globally and is notoriously difficult to diagnose early. By the time symptoms like tremors or stiffness appear, significant and often irreversible neurological damage has usually occurred.
The new test, based on qPCR technology, detects subtle changes in RNA fragments—specifically RGTTCRA-tRF—that are linked to the early development of the disease. This allows for pre-symptomatic diagnosis, enabling earlier interventions that could delay or even prevent disease progression.
The study was led by PhD student Nimrod Madrer and supervised by Prof. Hermona Soreq at the Hebrew University of Jerusalem, in collaboration with Dr. Iddo Paldor of the Shaare Zedek Medical Center and Dr. Eyal Soreq of the University of Surrey and Imperial College London. The findings were published in the journal Aging Nature.
The test could be particularly valuable for individuals with a family history of Parkinson’s, genetic risk factors, or early non-motor symptoms such as REM sleep behavior disorder. It could also aid pharmaceutical companies in selecting candidates for clinical trials targeting early-stage disease.
Beyond diagnosis, the test may help track the effectiveness of treatments by monitoring RNA fragment levels over time, giving clinicians a powerful tool to personalize therapy.
With broader clinical trials underway, the test could soon be available in community clinics, making early Parkinson’s screening widely accessible for the first time.
A magnitude 5.5 earthquake struck off Japan’s Tokara Islands on Wednesday, with no tsunami warning issued but residents advised to remain vigilant.
The United States has rescinded licensing restrictions on ethane exports to China, allowing shipments to resume after a temporary halt and signalling progress in efforts to ease recent trade tensions.
Italy plans to grant approximately 500,000 work visas to non-EU nationals between 2026 and 2028, as announced in a cabinet statement. The initiative aims to address labor shortages by expanding legal immigration pathways
Following a deadly glacier collapse in Blatten, near the Swiss Alpine village of Kandersteg, the town is on high alert as melting permafrost and shifting rock threaten another potential disaster after it was buried a month ago.
Australian researchers have pioneered a low-cost and scalable plasma-based method to produce ammonia gas directly from air, offering a green alternative to the traditional fossil fuel-dependent Haber-Bosch process.
New artificial intelligence software is helping NHS hospitals in Hull reduce MRI scan times, enabling staff to scan more patients each day while improving accessibility for vulnerable groups.
France will impose its toughest outdoor smoking restrictions starting Monday, banning smoking at beaches, parks, playgrounds, and bus stops.
Scientists in Australia and the U.S. have developed an AI tool that could transform cancer care by revealing the hidden diversity of tumour cells and guiding more targeted therapies.
Singapore has launched its largest-ever study on paediatric food allergies, aiming to better understand and address the growing burden of allergic reactions among children.
Bill Gates says his foundation will not compensate for funding shortfalls caused by U.S. and UK aid cuts to global vaccination efforts, warning of rising child mortality as a result.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment